Procept Biorobotics Corp. ((PRCT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Procept Biorobotics Corp. is conducting a clinical study titled PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs to evaluate the performance and safety of the AQUABEAM Robotic System. This system is intended for the resection and removal of prostate tissue in patients with lower urinary tract symptoms and localized prostate cancer. The study aims to provide insights into the system’s effectiveness and safety over a 12-month period.
The intervention being tested is the Aquablation therapy, a minimally invasive, image-guided robotic treatment. It uses a high-velocity sterile saline waterjet to remove prostate tissue, offering a heat-free alternative to traditional methods. This procedure is performed using the AQUABEAM Robotic System, which allows for precise tissue removal guided by real-time imaging.
The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. Participants will undergo baseline and follow-up assessments to monitor outcomes and safety.
The study began on September 18, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This study could significantly impact Procept Biorobotics Corp.’s stock performance and investor sentiment by demonstrating the effectiveness of their AQUABEAM Robotic System. Success in this trial may enhance their competitive position in the medical device industry, particularly in the treatment of prostate conditions.
The study is ongoing, with further details available on the ClinicalTrials portal.